Literature DB >> 3190995

The effect of concurrent aspirin upon plasma concentrations of tenoxicam.

R O Day1, P D Paull, S Lam, B R Swanson, K M Williams, D N Wade.   

Abstract

1. The effect of chronic, high-dose aspirin therapy upon the disposition of a single dose and multiple doses of tenoxicam was examined in normal volunteers. 2. Aspirin caused a 24% drop in the t1/2 (P less than 0.005), a 49% rise in the volume of distribution (P less than 0.0003) and a 98% increase in the clearance (P less than 0.0001) of tenoxicam after a single dose of the tenoxicam. 3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment. 4. Tenoxicam percentage free measured in plasma from a normal volunteer was 0.56 +/- 0.05% over the tenoxicam concentration range 1-20 micrograms ml-1 and rose to 1.24 +/- 0.07% in the presence of aspirin 150 micrograms ml-1. 5. The effect of aspirin upon the disposition of tenoxicam was consistent with a competitive protein binding interaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190995      PMCID: PMC1386568          DOI: 10.1111/j.1365-2125.1988.tb03405.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Rapid determination of salicylate in biological fluids.

Authors:  P TRINDER
Journal:  Biochem J       Date:  1954-06       Impact factor: 3.857

2.  The aspirin-ibuprofen interaction in rheumatoid arthritis.

Authors:  D M Grennan; D G Ferry; M E Ashworth; R E Kenny; M Mackinnon
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

Review 3.  Anti-rheumatic drug interactions.

Authors:  R O Day; G G Graham; G D Champion; E Lee
Journal:  Clin Rheum Dis       Date:  1984-08

4.  Combination therapy with naproxen and aspirin in rheumatoid arthritis.

Authors:  R F Willkens; E J Segre
Journal:  Arthritis Rheum       Date:  1976 Jul-Aug

Review 5.  Aspects of the clinical pharmacology of non-steroidal anti-inflammatory drugs.

Authors:  G G Graham; R O Day; G D Champion; E Lee; K Newton
Journal:  Clin Rheum Dis       Date:  1984-08

Review 6.  Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs.

Authors:  M L Orme
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

7.  Metabolism of salicylate during chronic aspirin therapy.

Authors:  R H Rumble; P M Brooks; M S Roberts
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates.

Authors:  R O Day; D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

9.  Interaction of isoxicam with acetylsalicylic acid.

Authors:  M Esquivel; F Cussenot; R I Ogilvie; D S East; D H Shaw
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

10.  Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis.

Authors:  R O Day; D E Furst; S H Dromgoole; B Kamm; R Roe; H E Paulus
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

View more
  5 in total

Review 1.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Intraocular and plasma kinetics of tenoxicam in rabbits.

Authors:  M Del Puppo; M G Kienle; R Ratiglia; D Galimberti; G Acerbi; L Boerci; L Marabini; E Chiesara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

Review 3.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 4.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.